Cue Biopharma (CUE) Total Liabilities (2017 - 2025)
Cue Biopharma (CUE) has disclosed Total Liabilities for 9 consecutive years, with $15.8 million as the latest value for Q4 2025.
- Quarterly Total Liabilities rose 7.41% to $15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.8 million through Dec 2025, up 7.41% year-over-year, with the annual reading at $15.8 million for FY2025, 7.41% up from the prior year.
- Total Liabilities hit $15.8 million in Q4 2025 for Cue Biopharma, down from $18.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $27.2 million in Q2 2023 to a low of $14.7 million in Q4 2024.
- Historically, Total Liabilities has averaged $21.3 million across 5 years, with a median of $21.6 million in 2024.
- Biggest five-year swings in Total Liabilities: skyrocketed 120.91% in 2021 and later plummeted 39.9% in 2024.
- Year by year, Total Liabilities stood at $17.9 million in 2021, then skyrocketed by 42.95% to $25.6 million in 2022, then decreased by 4.52% to $24.4 million in 2023, then tumbled by 39.9% to $14.7 million in 2024, then grew by 7.41% to $15.8 million in 2025.
- Business Quant data shows Total Liabilities for CUE at $15.8 million in Q4 2025, $18.4 million in Q3 2025, and $22.5 million in Q2 2025.